Anti-TNFSF2/TNFa Antibody (hMAK195) is a humanized monoclonal antibody targeting tumor necrosis factor alpha (TNF-α/TNFSF2), serving as a biosimilar to Afelimomab. TNF-α is a critical pro-inflammatory cytokine primarily produced by macrophages and T cells, playing a central role in inflammatory responses, apoptosis, and immune regulation. hMAK195 specifically binds to both soluble and membrane-bound TNF-α, blocking their interaction with cell surface receptors (TNFR1 and TNFR2) and thereby inhibiting the activation of downstream NF-κB and MAPK signaling pathways. This antibody effectively neutralizes TNF-α-induced cytotoxicity and inflammatory cascades, making it a valuable tool for researching sepsis, rheumatoid arthritis, and other inflammatory diseases.